The MyoSure Reach device addresses the challenge of hard-to-reach uterine pathology by allowing access to the upper third of the uterine cavity.

The company said the MyoSure tissue removal system is designed to provide a simple and quick solution for women with polyps and fibroids, which often cause abnormal uterine bleeding (AUB).

Hologic medical affairs vice president and medical director Edward Evantash said: "The ability to remove hard-to-reach intrauterine pathology is an important enhancement for the MyoSure system, and it demonstrates Hologic’s dedication to women’s health.

"The MyoSure Reach device offers the benefits of the current device, plus expanded capabilities to remove pathology in the upper third of the uterine cavity."

The new product will be showcased at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting in Washington, D.C., which is being held from 14 to 17 May.

Hologic is engaged in the development and manufacturing of diagnostic products, medical imaging systems and surgical products. The company also produces MyoSure XL and MyoSure LITE devices.